Apixaban and eftrenonacog alfa treatment in a patient with moderate hemophilia B and cardiovascular disease

Abstract

In developed countries, the life expectancy of patients with hemophilia (PwH) is now close to that of the unaffected male population. This means that these patients are at risk of developing age-related comorbidities, including cardiovascular disease. Managing cardiovascular disease in PwH patients can be particularly challenging, due to their high bleeding risk. To our knowledge, this is the first report of a male patient with moderate hemophilia B and hypertensive ischemic heart disease complicated by arrhythmia due to nonvalvular atrial fibrillation, who was treated with apixaban and left atrial appendage closure while receiving concomitant anti-hemorrhagic prophylaxis with eftrenonacog alfa.

Keywords

• Apixaban
• atrial fibrillation
• factor IX Fc fusion protein
• hemophilia B
• cardiovascular surgical procedures